The stock's rise snapped a four-day losing streak.

Fintel reports that on February 28, 2025, Stifel downgraded their outlook for Vertex (NasdaqGM:VERX) from Buy to Hold.

Vertex, Inc. (NASDAQ:VERX – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the thirteen research firms that are currently covering the company, MarketBeat.com reports.

BMO Capital analyst Daniel Jester lowered the firm’s price target on Vertex (VERX) to $41 from $56 and keeps a Market Perform rating on the ...

Baird lowered the firm’s price target on Vertex (VERX) to $45 from $62 and keeps an Outperform rating on the shares. The firm updated its model ...

Vertex has backed out of its in vivo gene editing collaboration with Verve Therapeuti | Vertex has backed out of its in vivo ...

Vertex Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), a global provider of tax technology solutions, today announced the ...

Arc’teryx unveils its 2025 footwear lineup, featuring the Norvan LD 4, Vertex Speed, and Konseal, designed to enhance ...

We recently compiled a list of the 10 Stocks Drop by Double Digits Mostly Due to Disappointing Earnings. In this article, we ...

KING OF PRUSSIA, Pa. — KING OF PRUSSIA, Pa. — Vertex, Inc. (VERX) on Thursday reported a loss of $67.8 million in its fourth quarter. On a per-share basis, the King Of Prussia, Pennsylvania-based ...

"If we do our jobs right, and you come back a year from now, this place is going to be a buzzing hive" -- Vertex Executive ...

The companies were two years into a four-year, $400 million agreement aimed at developing and marketing gene therapies ...